Innovative Research Pipeline
Glenmark’s innovative pipeline is focused on three core therapeutic areas: oncology, immunology and pain. Our pipeline demonstrates our efforts to solve some of medicine’s most difficult challenges and discover molecular entities that may one day have a major impact on how people live. With hundreds of scientists dedicated to new chemical entity (NCE) research and new biologic entity (NBE) research, we have developed an enviable and robust pipeline anchored in first- and best-in-class discovery. With NBEs, and NCEs various stages of clinical development, Glenmark is delivering on its commitment to bring the best science to patients worldwide.
Glenmark thanks all the volunteers who participate in our clinical trials. They are vital to our research advancement. To learn more about our clinical trials, please visit www.clinicaltrials.gov.
HER2 positive cancers such as breast cancer
OX40 Antagonist (mAb)
TRPA 1 antagonist
Pipeline as of August 1, 2019